Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 39 results:
Συντάκτης Τίτλος Τύπος [ Έτος(Asc)]
Φίλτρα: Συντάκτης is Gogas, Helen  [Clear All Filters]
2020
Fountzilas, E., Kotoula V., Koliou G-A., Giannoulatou E., Gogas H., Papadimitriou C., et al. (2020).  Pathogenic mutations and overall survival in 3,084 patients with cancer: the Hellenic Cooperative Oncology Group Precision Medicine Initiative.. Oncotarget. 11(1), 1-14.
Koletsa, T., Kotoula V., Koliou G-A., Manousou K., Chrisafi S., Zagouri F., et al. (2020).  Prognostic impact of stromal and intratumoral CD3, CD8 and FOXP3 in adjuvantly treated breast cancer: do they add information over stromal tumor-infiltrating lymphocyte density?. Cancer Immunol Immunother.
Razis, E., Kalogeras K. T., Kotsantis I., Koliou G-A., Manousou K., Wirtz R., et al. (2020).  The Role of CXCL13 and CXCL9 in Early Breast Cancer.. Clin Breast Cancer. 20(1), e36-e53.
Nikolaidi, A., Kotoula V., Koliou G-A., Giannoulatou E., Papadopoulou K., Zagouri F., et al. (2020).  Tumor Mutational Patterns and Infiltrating Lymphocyte Density in Young and Elderly Patients With Breast Cancer.. Cancer Genomics Proteomics. 17(2), 181-193.
2019
Lazaridis, G., Kotoula V., Vrettou E., Kostopoulos I., Manousou K., Papadopoulou K., et al. (2019).  Opposite Prognostic Impact of Single PTEN-loss and Mutations in Early High-risk Breast Cancer.. Cancer Genomics Proteomics. 16(3), 195-206.
2018
Batistatou, A., Kotoula V., Bobos M., Kouvatseas G., Zagouri F., Tsolaki E., et al. (2018).  Correlation of MYC Gene and Protein Status With Breast Cancer Subtypes and Outcome of Patients Treated With Anthracycline-Based Adjuvant Chemotherapy. Pooled Analysis of 2 Hellenic Cooperative Group Phase III Trials.. Clin Breast Cancer. 18(1), 53-62.e3.
2017
Psyrri, A., Kalogeras K. T., Wirtz R. M., Kouvatseas G., Karayannopoulou G., Goussia A., et al. (2017).  Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group.. J Transl Med. 15(1), 30.
Kotoula, V., Fostira F., Papadopoulou K., Apostolou P., Tsolaki E., Lazaridis G., et al. (2017).  The fate of BRCA1-related germline mutations in triple-negative breast tumors.. Am J Cancer Res. 7(1), 98-114.
Levva, S., Kotoula V., Kostopoulos I., Manousou K., Papadimitriou C., Papadopoulou K., et al. (2017).  Prognostic Evaluation of Epidermal Growth Factor Receptor (EGFR) Genotype and Phenotype Parameters in Triple-negative Breast Cancers.. Cancer Genomics Proteomics. 14(3), 181-195.
Strati, T-M., Kotoula V., Kostopoulos I., Manousou K., Papadimitriou C., Lazaridis G., et al. (2017).  Prognostic Subcellular Notch2, Notch3 and Jagged1 Localization Patterns in Early Triple-negative Breast Cancer.. Anticancer Res. 37(5), 2323-2334.
2016
Stavridi, F., Kalogeras K. T., Pliarchopoulou K., Wirtz R. M., Alexopoulou Z., Zagouri F., et al. (2016).  Comparison of the Ability of Different Clinical Treatment Scores to Estimate Prognosis in High-Risk Early Breast Cancer Patients: A Hellenic Cooperative Oncology Group Study.. PLoS One. 11(10), e0164013.
Kotoula, V., Karavasilis V., Zagouri F., Kouvatseas G., Giannoulatou E., Gogas H., et al. (2016).  Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes.. Breast Cancer Res Treat. 158(2), 307-21.
Lakis, S., Dimoudis S., Kotoula V., Alexopoulou Z., Kostopoulos I., Koletsa T., et al. (2016).  Interaction Between Beta-Catenin and EGFR Expression by Immunohistochemistry Identifies Prognostic Subgroups in Early High-risk Triple-negative Breast Cancer.. Anticancer Res. 36(5), 2365-78.
Gogas, H., Kotoula V., Alexopoulou Z., Christodoulou C., Kostopoulos I., Bobos M., et al. (2016).  MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer.. J Transl Med. 14(1), 136.
Fountzilas, G., Giannoulatou E., Alexopoulou Z., Zagouri F., Timotheadou E., Papadopoulou K., et al. (2016).  TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.. Oncotarget. 7(22), 32731-53.
Kotoula, V., Lakis S., Vlachos I. S., Giannoulatou E., Zagouri F., Alexopoulou Z., et al. (2016).  Tumor Infiltrating Lymphocytes Affect the Outcome of Patients with Operable Triple-Negative Breast Cancer in Combination with Mutated Amino Acid Classes.. PLoS One. 11(9), e0163138.
Kotoula, V., Chatzopoulos K., Lakis S., Alexopoulou Z., Timotheadou E., Zagouri F., et al. (2016).  Tumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: a pooled analysis of four prospective adjuvant trials.. Oncotarget. 7(4), 5074-87.
2015
Koutras, A., Kalogeras K. T., Wirtz R. M., Alexopoulou Z., Bobos M., Zagouri F., et al. (2015).  Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study.. J Transl Med. 13, 171.
Papaxoinis, G., Kotoula V., Alexopoulou Z., Kalogeras K. T., Zagouri F., Timotheadou E., et al. (2015).  Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study.. PLoS One. 10(10), e0140293.
2014
Kotoula, V., Bobos M., Alexopoulou Z., Papadimitriou C., Papadopoulou K., Charalambous E., et al. (2014).  Adjusting breast cancer patient prognosis with non-HER2-gene patterns on chromosome 17.. PLoS One. 9(8), e103707.
Koletsa, T., Stavridi F., Bobos M., Kostopoulos I., Kotoula V., Eleftheraki A. G., et al. (2014).  alphaB-crystallin is a marker of aggressive breast cancer behavior but does not independently predict for patient outcome: a combined analysis of two randomized studies.. BMC Clin Pathol. 14, 28.
Mountzios, G., Aivazi D., Kostopoulos I., Kourea H. P., Kouvatseas G., Timotheadou E., et al. (2014).  Differential expression of the insulin-like growth factor receptor among early breast cancer subtypes.. PLoS One. 9(3), e91407.
Fountzilas, G., Dafni U., Papadimitriou C., Timotheadou E., Gogas H., Eleftheraki A. G., et al. (2014).  Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial.. BMC Cancer. 14, 515.
Pancoska, P., Kirkwood J. M., Bouros S., Spyropoulou-Vlachou M., Pectasides E., Tsoutsos D., et al. (2014).  A new mathematical model for the interpretation of translational research evaluating six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon.. PLoS One. 9(1), e86375.
2013
Fountzilas, G., Dafni U., Bobos M., Kotoula V., Batistatou A., Xanthakis I., et al. (2013).  Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy.. BMC Cancer. 13, 163.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.

           

Σύνδεσμοι

 

Το πανεπιστήμιο

 
 

Προσωπικό & Φοιτητές